Polycystic Ovary Syndrome, Type2 Diabetes
Conditions
Brief summary
The study is prepared to use CMR technology for early screening of myocardial lesions in 561 age-matched women with type 2 diabetes without PCOS, with PCOS without type 2 diabetes and with type 2 diabetes combined with PCOS, compare the differences between the two groups of cardiomyocyte injury changes, and treat and follow-up with type 2 diabetes and PCOS in accordance with the current standard treatment guidelines for type 2 diabetes and PCOS, after 3 years of follow-up we will analyse the changes in cardiomyopathy, cardiac serological indicators, and heart function indicators,which can provide theoretical basis for early clinical intervention in the future.
Detailed description
So far, due to the lack of more sensitive noninvasive detection methods and indicators that suggest early cardiomyopathy, it is not clear whether type 2 diabetes combined with PCOS will lead to earlier and more progressive changes in cardiomyopathy, and whether there is a difference with type 2 diabetes alone and early cardiomyopathy in patients with simple PCOS.Compared with women with type 2 diabetes who did not combine polycystic Ovary Syndrome(PCOS) or PCOS did not combine with type 2 diabetes, patients with type 2 diabetes who combined PCOS had the characteristics of lower age of onset, longer exposure to high risk factors of CVD, and higher risk of cardiovascular disease on the basis of the dual pathophysiology of insulin resistance and hyperandrogenism.The purpose of this study is to find early cardiovascular disease of women with type 2 diabetes and PCOS and conduct early clinical intervention.
Interventions
None listed
Sponsors
RenJi Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Age 30-40 years old; 2. Overweight and obese women with/without type 2 diabetes without PCOS, PCOS without type 2 diabetes, and type 2 diabetes with PCOS; 3. HbA1C 7-9% of patients with type 2 diabetes; 4. Increased risk of cardiovascular disease (with any one of the following risk factors: hypertension, dyslipidemia, hyperuricemia, obesity, smoking); 5. The diagnosis of PCOS is based on the 2003 Rotterdam criteria, the diagnosis of overweight/obesity is based on the WHO-WPR criteria, and the diagnosis criteria of type 2 diabetes is based on the 1998 WHO diagnosis criteria; 6. Willing to participate in this study and sign an informed consent form.
Exclusion criteria
1. Severe liver and kidney dysfunction (ALT is greater than 2.5 times the upper limit of normal, or Cr\>132umol/l, or eGFR \<60 mL/min/1.73m2), psychosis, accompanied by severe infection, severe anemia, neutropenia disease; 2. Congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy, atrial fibrillation, viral myocarditis, infectious myocarditis, hyperthyroid heart disease, cardiac amyloidosis and other myocardial damage diseases, NYHA heart function classification ≥ Grade III, or the subject has had a clinical cardiovascular event in the past 3 months; 3. Symptomatic heart failure in the past 6 months, or left ventricular ejection fraction \<35%; 4. Self-reported or medical records are type 1 diabetes, single-gene mutation diabetes, diabetes caused by pancreatic injury, or other secondary diabetes (such as diabetes caused by Cushing syndrome, abnormal thyroid function, or acromegaly) ； 5. Pregnancy; 6. Participated in clinical trials of other drugs within 3 months; 7. In the past 5 years, there have been treated or untreated organ system tumors (except local skin basal cell carcinoma), regardless of whether there is evidence of local recurrence or metastasis; 8. A history of psychoactive substance abuse, including alcohol and a history of alcohol-related illnesses in the past 2 years; 9. The subject is allergic to the contrast agent (gadopentetate meglumine injection); 10. The subject has claustrophobia; 11. The subject contains metal implants that are not suitable for cardiac magnetic resonance examination; 12. Any conditions judged by the investigator that affect enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the change level of cardiac extracellular volume (ECV) | 3 years | Compared with baseline, the change level of cardiac extracellular volume (ECV) in patients with type 2 diabetes without PCOS, PCOS without type 2 diabetes, and type 2 diabetes with PCOS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in the level of creatine kinase isoenzymes (CK-MB) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the serum index related to myocardial injury such as change of CK-MB in IU/L. |
| change in the level of Brain Natriuretic Peptide (BNP) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the serum index related to myocardial injury such as change of BNP in pg/ml. |
| change in the level of atrialnatriureticpeptide (ANP) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the serum index related to myocardial injury such as change of ANP in pg/ml. |
| change in the level of left ventricular ejection fraction (LVEF) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the cardiac functions change such as: left ventricular ejection fraction (LVEF) in %. |
| change in the level of left ventricular end diastolic pressure (LVEDP) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the cardiac functions change such as: left ventricular end diastolic pressure (LVEDP) in kPa/mmHg. |
| change in the level of troponin I (TNI) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the serum index related to myocardial injury such as change of TNI in ng/ml. |
| change in the level of left ventricular diameter reduction rate (FS) | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the cardiac functions change such as: left ventricular diameter reduction rate (FS) in %. |
| Changes in score of Minnesota heart failure quality of life scale(LiHFe) | 3 years | Compared with the baseline in three groups, the changes of Minnesota heart failure quality of life scale(LiHFe) in score, higher scores mean a worse outcome. (Scores ranging from 0 to 105) |
| Changes in score of short form 12 questionnaire(SF-12) | 3 years | Compared with the baseline in three groups, the changes of SF-12 in score, higher scores mean a better outcome. (Scores ranging from 0 to 65) |
| Changes in score of Generalized Anxiety Disorder-7(GAD-7) | 3 years | Compared with the baseline in three groups, the changes of GAD-7 in score, higher scores mean a worse outcome. (Scores ranging from 0 to 21) |
| Changes in score of Patient Health Questionnaire-9(PHQ-9) | 3 years | Compared with the baseline in three groups, the changes of PHQ-9 in score, higher scores mean a worse outcome. (Scores ranging from 0 to 27) |
| change in the level of output per minute (CO) in L/min | 3 years | Compared with the baseline in three groups and T2DM with different phenotype of PCOS, the cardiac functions change such as: output per minute (CO) in L/min. |
Countries
China
Contacts
Primary ContactTao Tao, Dr.
Outcome results
None listed